Toggle navigation

We understand that for a caregiver or individual living with spinal muscular atrophy (SMA), life can be challenging. SMA360° is a support service from Biogen created to help families navigate the SPINRAZA treatment journey.*

TREATMENT LOGISTICS

Once a completed Start Form has been submitted to Biogen, a dedicated Family Access Manager (FAM) will reach out to begin helping with the logistics surrounding treatment. The FAM will be the go-to person whenever there is a question or concern related to the logistics of the treatment journey while on SPINRAZA. The FAM can provide information on SMA360° support services and how a caregiver or individual living with SMA may be eligible for programs tailored to their needs.

The FAM can:

  • Coordinate the logistics of getting started with treatment
  • Prepare the individual with SMA for the treatment journey by educating him/her on what to expect
  • Connect with the caregiver or individual with SMA at the treatment center, if he/she chooses, to help with logistics as necessary

For a caregiver or individual living with SMA, the relationship they have with their FAM should be one that's comfortable.

INSURANCE AND FINANCIAL ASSISTANCE

Today’s ever-changing insurance landscape can be overwhelming. SMA360° Insurance and Financial Assistance Programs are designed to help individuals with SMA and their families understand their insurance benefits for SPINRAZA, and find an affordable way to start treatment and continue as prescribed by their healthcare provider.

To help inform decisions, Lead Case Managers (LCM) can:

  • Investigate insurance benefits to help individuals with SMA and their families understand their current coverage
  • Collaborate with healthcare providers so that they can obtain prior authorizations for treatment
  • Provide support in the event of denied insurance claims
  • Educate individuals with SMA and their families on the eligibility details of the $0 Copay Program from Biogen, which can potentially cover both the SPINRAZA prescription and the treatment procedure
  • Supply background and resources for referral to third-party charity organizations
  • Counsel individuals with SMA and their families on the possibility of adding or changing insurance coverage 

TREATMENT LOGISTICS

Once a completed Start Form has been submitted to Biogen, a dedicated Family Access Manager (FAM) will reach out to begin helping with the logistics surrounding treatment. The FAM will be the go-to person whenever there is a question or concern related to the logistics of the treatment journey while on SPINRAZA. The FAM can provide information on SMA360° support services and how a caregiver or individual living with SMA may be eligible for programs tailored to their needs.

The FAM can:

  • Coordinate the logistics of getting started with treatment
  • Prepare the individual with SMA for the treatment journey by educating him/her on what to expect
  • Connect with the caregiver or individual with SMA at the treatment center, if he/she chooses, to help with logistics as necessary

For a caregiver or individual living with spinal muscular atrophy (SMA), the relationship they have with their FAM should be one that's comfortable.

INSURANCE AND FINANCIAL ASSISTANCE

Today’s ever-changing insurance landscape can be overwhelming. SMA360° Insurance and Financial Assistance Programs are designed to help individuals with SMA and their families understand their insurance benefits for SPINRAZA, and find an affordable way to start treatment and continue as prescribed by their healthcare provider.

To help inform decisions, Lead Case Managers (LCM) can:

  • Investigate insurance benefits to help individuals with SMA and their families understand their current coverage
  • Collaborate with healthcare providers so that they can obtain prior authorizations for treatment
  • Provide support in the event of denied insurance claims
  • Educate individuals with SMA and their families on the eligibility details of the $0 Copay Program from Biogen, which can potentially cover both the SPINRAZA prescription and the treatment procedure
  • Supply background and resources for referral to third-party charity organizations
  • Counsel individuals with SMA and their families on the possibility of adding or changing insurance coverage 

Download a patient support brochure to share with your patients.

Enroll your patients in SMA360°. Download a Start Form here.

*SMA360° services from Biogen are available only to those who have been prescribed SPINRAZA. SMA360° is intended for US residents only.
†Depending on the individual’s income or, in some cases, if their medication is obtained from an out-of-network provider, there may be an annual cap that limits the amount of assistance they can receive over 1 year. Federal and state laws and other factors may prevent or otherwise restrict eligibility. Individuals receiving coverage from Medicare, Medicaid, the VA/DoD, TRICARE®, or any other governmental or pharmaceutical assistance may not be eligible. The $0 Copay Program is only available once a claim has been submitted to and paid for by the insurance company. Individuals may remain enrolled in the $0 Copay Program for as long as eligibility criteria are met. Contact a Lead Case Manager for full eligibility requirements.
TRICARE is a registered trademark of the Department of Defense (DoD), DHA. All rights reserved.

Key Icon

The SMA360° team is made up of the Family Access Manger (FAM) and the Lead Case Manager (LCM). As your patients explore each area of service, they will discover the roles their team members play in their treatment experience.

Photo of Emma aged 7 years old with Type 3 SMA on a swing
Emma
age 7

Later-onset (Type 3) SMA treated with SPINRAZA

Individual results may vary based on several factors, including severity of disease and duration of therapy.

INDICATION

SPINRAZA is indicated for the treatment of spinal muscular atrophy (SMA) in pediatric and adult patients.

IMPORTANT SAFETY INFORMATION

Coagulation abnormalities and thrombocytopenia, including acute severe thrombocytopenia, have been observed after administration of some antisense oligonucleotides. Patients may be at increased risk of bleeding complications. Perform a platelet count and coagulation laboratory testing at baseline and prior to each administration of SPINRAZA and as clinically needed.

In a clinical study, 11% of SPINRAZA-treated patients with normal or above normal platelet levels at baseline developed a platelet level below the lower limit of normal compared to zero sham-procedure control patients. No patient had a platelet count <50,000 cells per mcL and no patient developed a sustained low platelet count despite continued drug exposure.

Renal toxicity, including potentially fatal glomerulonephritis, has been observed after administration of some antisense oligonucleotides.

SPINRAZA is present in and excreted by the kidney. In a clinical study (mean treatment exposure 7 months), 33% of SPINRAZA-treated patients had elevated urine protein, compared to 20% of sham-control patients. In a group of later-onset SMA patients (mean treatment exposure 34 months), 69% had elevated urine protein.

No elevations in serum creatinine or cystatin C were observed in studies with SPINRAZA. Conduct quantitative spot urine protein testing (preferably using a first morning urine specimen) at baseline and prior to each dose of SPINRAZA. For urinary protein concentration >0.2 g/L, consider repeat testing and further evaluation.

Severe hyponatremia was reported in an infant treated with SPINRAZA requiring salt supplementation for 14 months.

Cases of rash were reported in patients treated with SPINRAZA.

SPINRAZA may cause a reduction in growth as measured by height when administered to infants, as suggested by observations from the controlled study. It is unknown whether any effect of SPINRAZA on growth would be reversible with cessation of treatment.

The most common adverse reactions that occurred in the controlled study in at least 20% of SPINRAZA-treated patients and occurred at least 5% more frequently than in control patients were upper respiratory infection (39% vs 34%), lower respiratory infection (43% vs 29%), and constipation (30% vs 22%). Serious adverse reactions of atelectasis were more frequent in SPINRAZA-treated patients (14%) than in control patients (5%). Because patients in the controlled study were infants, adverse reactions that are verbally reported could not be assessed in this study. In the open-label studies, the most common adverse events in later onset patients were headache (50%), back pain (41%) and post lumbar puncture syndrome (41%).

Please see full Prescribing Information for additional Important Safety Information.

As a courtesy, our full Prescribing Information is also available en Español. For prescribing decisions, please refer to official approved labeling.